Exhibit 16.1
September 27, 2018
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Ladies and Gentlemen:
We have read the statements made by CASI Pharmaceuticals, Inc. in its Form 8-K dated September 27, 2018, which we understand will be filed with the Commission pursuant to Item 4 of Form 8-K. We agree with the statements concerning our Firm in such Form 8-K.
Very truly yours,
/s/ CohnReznick LLP